CN110028462B - Method for preparing isoxazoline intermediate and isoxazoline - Google Patents

Method for preparing isoxazoline intermediate and isoxazoline Download PDF

Info

Publication number
CN110028462B
CN110028462B CN201910292049.1A CN201910292049A CN110028462B CN 110028462 B CN110028462 B CN 110028462B CN 201910292049 A CN201910292049 A CN 201910292049A CN 110028462 B CN110028462 B CN 110028462B
Authority
CN
China
Prior art keywords
reaction
ethyl acetate
solution
water
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910292049.1A
Other languages
Chinese (zh)
Other versions
CN110028462A (en
Inventor
李冰冰
姜桥
朱君琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Livzon New North River Pharmaceutical Co ltd
Original Assignee
Livzon New North River Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Livzon New North River Pharmaceutical Co ltd filed Critical Livzon New North River Pharmaceutical Co ltd
Priority to CN201910292049.1A priority Critical patent/CN110028462B/en
Publication of CN110028462A publication Critical patent/CN110028462A/en
Application granted granted Critical
Publication of CN110028462B publication Critical patent/CN110028462B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention discloses a method for preparing isoxazoline intermediate and isoxazoline, and intermediateThe preparation comprises using

Description

Method for preparing isoxazoline intermediate and isoxazoline
Technical Field
The invention relates to the field of chemical industry, in particular to a compound intermediate and preparation of a compound, and specifically relates to a method for preparing an isoxazoline intermediate and isoxazoline.
Background
Isoxazolines are a new class of highly potent insecticides that die by interfering with the parasite's gamma-aminobutyric acid (GABA) gated chloride channel leading to its nervous system being over-excited. Compared with the traditional pesticide, the isoxazoline compound has obvious differences in the aspects of target, molecular structure, selectivity and the like. The isoxazoline compound is mainly used for treating parasites of pet cats or dogs, such as fleas, ticks and the like.
The compounds shown in the following formulas 1-1, 1-2 and 1-3 are important intermediates for synthesizing 3 isoxazoline insecticides, and are simply the compounds shown in the general formula 1.
Figure BDA0002025228450000011
Figure BDA0002025228450000021
The routes reported in the literature for synthesizing the compounds of formula 1-1 and formula 1-2 are shown in scheme 1(WO2008122375A2, CN102149695A, R ═ Me; WO2009080250A2, R ═ t-Bu) and scheme 2(CN101765592A, R ═ Me), respectively.
Figure BDA0002025228450000022
Figure BDA0002025228450000031
The synthetic routes shown in scheme 1 and scheme 2 are simplified to the general formula scheme 3.
Figure BDA0002025228450000032
In the general formula route 3, corresponding p-aldehyde aromatic carboxylic acid is used as a raw material, and 4 steps of esterification, hydroxylamine oximation, substitution and elimination (obtaining nitrile oxide), cyclization and hydrolysis are performed to obtain an isoxazoline intermediate.
In the above route, the intermediate is an oil, except for the starting material and the product. The oily intermediate not only brings inconvenience to the material feeding in the reaction process, but also increases the difficulty of impurity purification, reduces the purity of the intermediate and the product, and finally causes adverse effects on the quality and yield of the product.
Therefore, how to prepare high-quality isoxazoline intermediates with low cost and high efficiency is a problem to be solved.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a production process of an isoxazoline intermediate with mild reaction conditions and low impurity content.
The technical scheme adopted by the invention is as follows:
a method for preparing an isoxazoline intermediate, the structural general formula of the isoxazoline intermediate is shown as a compound formula 1,
Figure BDA0002025228450000041
the synthetic route is as follows:
Figure BDA0002025228450000042
the method comprises the following operations:
hydroxylamine oximation reaction: reacting the intermediate-0 with hydroxylamine hydrochloride in a solvent; after the reaction is finished, an intermediate-1 is obtained by extraction, separation and concentration;
and (3) substitution reaction: reacting the intermediate-1, N-halogenated succinimide in a solvent; after the reaction is finished, adding water to precipitate out a solid, and then filtering and drying to obtain an intermediate 2-1;
elimination&And (3) cyclization reaction: intermediate 2-1, trifluoromethyl ethylene intermediate
Figure BDA0002025228450000051
Reacting in a solvent; after the reaction is finished, an intermediate 1-1 or 1-2 or 1-3 is obtained through post-treatment.
In some examples, the temperature of the hydroxylamine oximation reaction is from 15 ℃ to the solvent reflux temperature.
In some examples, the solvent of the hydroxylamine oximation reaction is a basic solvent.
In some examples, the base in the basic solvent of the hydroxylamine oximation reaction is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, N-diisopropylethylamine, sodium acetate, potassium acetate, sodium bicarbonate, or mixtures thereof.
In some examples, the solvent of the hydroxylamine oximation reaction is selected from: a mixed solution of water and at least one of methanol, ethanol, N-propanol, isopropanol, tetrahydrofuran, benzene, toluene, N-dimethylformamide, 1, 4-dioxane, dimethyl sulfoxide and acetonitrile.
In some examples, the solvent of extraction is selected from ethyl acetate, toluene, dichloromethane, ethyl acetate, chloroform, butyl acetate, carbon tetrachloride, diethyl ether.
A method for preparing isoxazoline compounds, which is characterized by comprising the following steps:
1) preparing an isoxazoline intermediate shown in a compound formula 1 according to the method;
2) isoxazoline intermediates
Figure BDA0002025228450000052
And
Figure BDA0002025228450000053
amidation reaction to obtain isoOxazoline compounds.
The invention has the beneficial effects that:
the method has mild reaction conditions, is easy to realize industrially, and can obtain the isoxazoline intermediate with low impurity.
The invention has safe raw materials and low cost, and effectively reduces the production cost.
Compared with the prior route 3, the method adjusts the original 4-step reaction (esterification, hydroxylamine oximation, substitution & elimination (obtaining nitrile oxide), cyclization and hydrolysis) into 2-step reaction (hydroxylamine oximation, substitution & elimination (obtaining nitrile oxide) & cyclization). The adjusted process reduces the esterification and hydrolysis steps, and simultaneously, the prepared intermediate can be separated into solid, thereby facilitating the delivery of materials in the reaction process. Furthermore, the method of the invention reduces the difficulty of intermediate purification, improves the product quality and yield, and finally improves the product competitiveness.
Detailed Description
A method for preparing an isoxazoline intermediate, the structural general formula of the isoxazoline intermediate is shown as a compound formula 1,
Figure BDA0002025228450000061
the synthetic route is as follows:
Figure BDA0002025228450000062
the method comprises the following operations:
hydroxylamine oximation reaction: reacting the intermediate-0 with hydroxylamine hydrochloride in a solvent; after the reaction is finished, an intermediate-1 is obtained by extraction, separation and concentration;
and (3) substitution reaction: reacting the intermediate-1, N-halogenated succinimide in a solvent; after the reaction is finished, adding water to precipitate out a solid, and then filtering and drying to obtain an intermediate 2-1;
elimination&And (3) cyclization reaction: intermediate 2-1, trifluoromethylEthylene intermediates
Figure BDA0002025228450000063
Reacting in a solvent; after the reaction is finished, an intermediate 1-1 or 1-2 or 1-3 is obtained through post-treatment.
In some examples, the temperature of the hydroxylamine oximation reaction is from 15 ℃ to the solvent reflux temperature.
In some examples, the solvent of the hydroxylamine oximation reaction is a basic solvent.
In some examples, the base in the basic solvent of the hydroxylamine oximation reaction is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, N-diisopropylethylamine, sodium acetate, potassium acetate, sodium bicarbonate, or mixtures thereof.
In some examples, the solvent of the hydroxylamine oximation reaction is selected from: a mixed solution of water and at least one of methanol, ethanol, N-propanol, isopropanol, tetrahydrofuran, benzene, toluene, N-dimethylformamide, 1, 4-dioxane, dimethyl sulfoxide and acetonitrile.
Hydroxylamine oximation is a classical chemical reaction, as defined by the company chen, xu rui qiu et al, basic organic chemistry, under 2 nd edition, beijing: higher education publishers, 1983.09, etc. are described in more detail. In some embodiments, the reaction temperature for the hydroxylamine oximation reaction is from 15 ℃ to the solvent reflux temperature, preferably room temperature. The reaction temperature is increased, which is beneficial to accelerating the reaction speed and simultaneously obtaining a product with higher purity. Generally speaking, the reaction can be carried out at room temperature without deliberately raising the temperature, so that satisfactory reaction results can be obtained, energy conservation is facilitated, and control of reaction conditions is reduced.
The hydroxylamine oximation reaction has no special requirements, and can be a base commonly used in the hydroxylamine oximation reaction. The available base can be selected by those skilled in the art according to actual needs, and the type of the base has no significant influence on the reaction. In some embodiments, the base in the basic solvent of the hydroxylamine oximation reaction is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, N-diisopropylethylamine, sodium acetate, potassium acetate, sodium bicarbonate, or mixtures thereof.
The solvent has better solubility to the reactants, and the type of the solvent has no special requirement. In some embodiments, the solvent of the hydroxylamine oximation reaction is selected from: a mixed solution of water and at least one of methanol, ethanol, N-propanol, isopropanol, tetrahydrofuran, benzene, toluene, N-dimethylformamide, 1, 4-dioxane, dimethyl sulfoxide and acetonitrile.
The extraction solvent may be determined according to the characteristics of the reaction product, and the same or different extraction solvents may be selected for different reaction products. In some examples, the solvent of extraction is selected from ethyl acetate, toluene, dichloromethane, ethyl acetate, chloroform, butyl acetate, carbon tetrachloride, diethyl ether.
A method for preparing isoxazoline compounds, which is characterized by comprising the following steps:
1) preparing an isoxazoline intermediate shown in a compound formula 1 according to the method;
2) isoxazoline intermediates
Figure BDA0002025228450000071
And
Figure BDA0002025228450000072
carrying out amidation reaction to obtain the isoxazoline compound.
The amide condensation reaction is an extremely mature chemical reaction whose reaction conditions can be determined according to the prior art. For example, amide condensation conditions include: the condensation was carried out in DCC and DMAP with DCM as solvent. The condensation is carried out in DPPA and triethylamine by taking DMF as solvent. Toluene or dichloromethane or tetrahydrofuran is used as a solvent, and acyl chloride is formed in thionyl chloride and DMF for condensation.
To ensure the reaction is fully performed and avoid wasting materials, in some embodiments, the molar ratio of the intermediate to the reaction raw materials is 1: (1-1.5), 1: (1-1.2), 1: (1-1.1). If the molar ratio of the intermediate 0 to the hydroxylamine hydrochloride is 1: (1-1.5).
In order to further clarify the technical problems solved by the present invention and the effects of the technical solutions, the present invention will be further described with reference to the following examples.
In the following examples, unless otherwise indicated, the experimental method specific conditions are generally in accordance with conventional conditions or manufacturer's recommended practice conditions; the raw materials and the reagents are purchased from commercial products; the proportions, ratios, percentages or parts are by weight.
Example 1 (preparation of compound formula 1-1):
hydroxylamine oximation reaction
Figure BDA0002025228450000081
1) In a 500ml round bottom flask, 150ml of THF, 80ml of water and 023.5 g (0.14mol) of intermediate were sequentially added, and 11.2g (0.16mol) of hydroxylamine hydrochloride was added after the solution was dissolved by stirring, followed by 17.2g (0.21mol) of sodium acetate. Stirring the reaction solution at room temperature for 4 hours;
2) the reaction was stopped, and 200ml of water and 100ml of ethyl acetate (X3 times) were added to the reaction mixture to extract the aqueous phase. After combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
3) and distilling off ethyl acetate under reduced pressure at the temperature of 45-50 ℃ to obtain 122.6 g of an intermediate with the yield of 90.2%.
The intermediate-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=180.1。
Substitution reaction
Figure BDA0002025228450000091
4) 100ml of DMF, intermediate-122.6 g (0.13mol) and NCS18.7g (0.14mol) were added in this order to a 500ml round bottom flask, and after the mixture was stirred and dissolved, the mixture was heated at 40 ℃ for 2 hours;
5) the reaction was stopped and the solution was cooled to room temperature. 200ml of water was slowly added and a solid precipitated. Stirring was continued and cooling was carried out to 5 ℃. And filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate 2-125.5 g with the yield of 92.0%.
The intermediate-2-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=214.0。
Elimination & cyclization reaction
Figure BDA0002025228450000092
6) In a 500ml round bottom flask, 150ml of DMF, 2 to 125.5 g (0.12mol) of intermediate-and 35.0g (0.14mol) of trifluoroethylene intermediate were added successively with stirring. After the mixture solution is dissolved, 13.2g (0.13mol) of triethylamine is added, and the reaction is continued for 10 hours at room temperature;
7) the reaction was stopped, 200ml of water was added to the reaction solution, and 100ml of ethyl acetate was added to the reaction solution in this order, and the aqueous phase was extracted 3 times. After combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) and distilling off ethyl acetate under reduced pressure at the temperature of 45-50 ℃ to obtain an intermediate-2 crude product. The crude product was recrystallized from ethyl acetate/petroleum ether to yield-242.9 g of intermediate, 99.5% HPLC purity, 85.4% yield.
MS(m/z):[M+H]+=418.1。
1H NMR(400MHz,CDCl3)(ppm):8.10(d,1H),7.42-7.63(m,5H),4.12(d,1H),3.72(d,1H),2.72(s,3H)。
Example 2 (preparation of compound formula 1-2):
hydroxylamine oximation reaction
Figure BDA0002025228450000101
1) In a 500ml round bottom flask, 150ml of toluene, 50ml of water and 020.0 g (0.10mol) of intermediate were sequentially added, and 7.7g (0.11mol) of hydroxylamine hydrochloride was added after the solution was dissolved by stirring. Stirring the reaction solution under the condition of heating reflux for 2 hours;
2) the reaction was stopped, the layers were separated and the toluene phase was washed with 100ml × 3 times of water. Drying the toluene organic phase with anhydrous sodium sulfate;
3) and (3) evaporating toluene at 75-80 ℃ under reduced pressure to obtain-120.6 g of an intermediate with the yield of 96.0%.
The intermediate-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=216.1。
Substitution reaction
Figure BDA0002025228450000102
4) In a 500ml round bottom flask, acetonitrile 200ml, intermediate-120.6 g (0.09mol) and NBS 17.6g (0.10mol) were added in this order, and after the mixture was stirred to be clear, the reaction was refluxed for 2 hours;
5) the reaction was stopped and the solution was cooled to room temperature. 400ml of water was slowly added and a solid precipitated. Stirring was continued and cooling was carried out to 5 ℃. And filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate 2-125.3 g with the yield of 95.3%.
The intermediate-2-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=294.0。
Elimination & cyclization reaction
Figure BDA0002025228450000103
6) In a 500ml round bottom flask, 150ml of acetonitrile, 2 to 125.3 g (0.08mol) of intermediate-and 26.4g (0.96mol) of trifluoroethylene intermediate were sequentially added under stirring. After the mixture solution is dissolved, adding 9.1g (0.09mol) of triethylamine, heating and refluxing for continuous reaction for 3 hours;
7) the reaction was stopped, 300ml of water was added to the reaction solution, and 100ml of ethyl acetate was added to the reaction solution in this order, and the aqueous phase was extracted 3 times. After combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) and distilling off ethyl acetate under reduced pressure at the temperature of 45-50 ℃ to obtain a crude intermediate 2. The crude product was recrystallized from ethyl acetate/petroleum ether and intermediate-235.7 g, HPLC purity 99.6%, yield 91.6%.
MS(m/z):[M+H]+=488.1。
1H NMR(400MHz,CDCl3)(ppm):7.38-8.81(m,9H),4.15(d,1H),3.75(d,1H)。
Example 3 (preparation of compounds of formulae 1-3):
hydroxylamine oximation reaction
Figure BDA0002025228450000111
1) To a 500ml round bottom flask, DMF250ml, water 100ml and intermediate 034.0 g (0.20mol) were added in this order, and after the solution was stirred and dissolved, 15.3g (0.22mol) of hydroxylamine hydrochloride was added, followed by 29.4g (0.3mol) of potassium acetate. Stirring the reaction solution at 50 ℃ to react for 2 hours;
2) the reaction was stopped, and 300ml of water and 100ml of ethyl acetate, X3 times of extraction of the aqueous phase were added to the reaction mixture in this order. After combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
3) and distilling off ethyl acetate under reduced pressure at the temperature of 45-50 ℃ to obtain an intermediate product of-134.1 g with the yield of 92.1%.
The intermediate-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=186.1。
Substitution reaction
Figure BDA0002025228450000112
4) 250ml of acetonitrile, 134.1g (0.18mol) of intermediate and 27.0g (0.20mol) of NCS are sequentially added into a 500ml round-bottom flask, and after the mixture is stirred and dissolved, the mixture is heated and refluxed for 2 hours;
5) the reaction was stopped and the solution was cooled to room temperature. 500ml of water was slowly added and a solid precipitated. Stirring was continued and cooling was carried out to 5 ℃. And filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate 2-136.9 g with the yield of 93.5%.
The intermediate-2-1 can be directly put into the subsequent reaction without further treatment.
MS(m/z):[M+H]+=220.1。
Elimination & cyclization reaction
Figure BDA0002025228450000121
6) Into a 500ml round-bottom flask were charged, while stirring, 300ml of acetonitrile, 2 to 136.9 g (0.17mol) of intermediate-2 and 56.2g (0.20mol) of intermediate trifluoromethylethylene, in that order. After the mixture solution is dissolved, 18.9g (0.19mol) of triethylamine is added, and then the mixture is heated at 60 ℃ to continue the reaction for 5 hours;
7) the reaction was stopped, 600ml of water was added to the reaction solution, and 200ml of ethyl acetate was added to the reaction solution in this order, and the aqueous phase was extracted 3 times. After combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) and distilling off ethyl acetate under reduced pressure at the temperature of 45-50 ℃ to obtain an intermediate-2 crude product. Intermediate 268.8 g after recrystallization of the crude product from ethyl acetate/petroleum ether, HPLC purity 99.6%, yield 88.2%.
MS(m/z):[M+H]+=458.1。
1H NMR(400MHz,CDCl3)(ppm):7.24(s,2H),6.83(s,1H),2.63(d,1H),2.42(d,1H),2.35(s,3H)。
Comparative example 1: r ═ Me. The compound of formula 1-1 (see scheme 1) was prepared by the method disclosed in WO2008122375A2 (examples 5-1&5-2), CN 102149695A.
Comparative example 2: and R is t-Bu. The compounds of formula 1-1 (see scheme 1) were prepared by the method disclosed in WO2009080250A2 (example 118-120).
Comparative example 3: r ═ Me. CN101765592A (example 1, steps a, B, C) discloses a process for the preparation of compounds of formula 1-2 (see scheme 2).
The different methods for preparing isoxazoline intermediates are compared as follows:
TABLE 1 comparative tables of the preparation of isoxazoline intermediates in different comparative examples
Figure BDA0002025228450000131
Note 1: to simplify the evaluation, the yield data missing in the literature are calculated as 100%; note 2: NCS refers to N-chlorosuccinimide; the literature reports no purity data due to being an intermediate.
TABLE 2 comparative tables of the preparation of isoxazoline intermediates in the different examples
Figure BDA0002025228450000132
Note 1: NCS refers to N-chlorosuccinimide, NBS refers to N-bromosuccinimide.
As can be seen from the data in tables 1 and 2:
compared with comparative examples 1-3:
1) examples 1 to 3 are different in that the reaction steps of esterification and hydrolysis are reduced;
2) the total yield of the step 2-1 → 2-3 of the examples 1 to 3 is 78.6 to 87.3 percent, which is also obviously higher than the yield range of 32.1 to 65.3 percent of the same reaction step 3-1 → 3-3 of the comparative examples 1 to 3;
3) the purity of the intermediate in each of examples 1 to 3 was 99.5% or more.
In summary, the following steps: the embodiment 1-3 ensures that the product purity is greatly improved, and simultaneously, the product cost is greatly reduced by improving the total reaction yield, and the product competitiveness is obviously improved.
The comparative cases for the preparation of isoxazoline intermediates with different process parameters are as follows:
TABLE 3 comparative table of the preparation of isoxazoline intermediates with different process parameters
Figure BDA0002025228450000141
From the data in the table, it can be seen from the comparison of examples 1 to 3 that:
1) in reaction step 1 hydroxylamine oximation, more polar solvents, higher reaction temperature and stronger basicity (DMF &50℃ & potassium acetate VS example 1 THF & rt & sodium acetate) favoured higher yields (92.1% VS example 3 90.2% of example 1); meanwhile, the toluene solvent is used, so that the solvent recovery is more convenient while the higher yield (96.5%) is ensured;
2) in the reaction step 2-1 substitution reaction, more active solvents, reagents and higher reaction temperatures (acetonitrile & NBS & reflux VS example 1 DMF & NCS &40 ℃) favoured higher yields (95.3% VS example 1 of example 2 92.0%) in the reaction step 2-1 substitution reaction;
3) in the elimination & cyclization reactions of reaction steps 2-3, the more active solvent and higher reaction temperature (acetonitrile & reflux VS example 1 DMF & room temperature of example 2) favor higher yields (91.6% VS example 1 of example 2 85.4%).
In summary, the following steps: by optimizing the process conditions, the overall yield of example 2 was also significantly improved compared to examples 1 and 3 while maintaining high product purity (84.2% VS of example 2 70.9% of example 1 and 76.0% of example 3).
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (3)

1. A method for producing an isoxazoline intermediate, characterized in that: the method comprises the following steps:
hydroxylamine oximation reaction:
Figure FDA0002657744610000011
1) 150ml of THF, 80ml of water and 023.5 g of intermediate are sequentially added into a 500ml round-bottom flask, 11.2g of hydroxylamine hydrochloride is added after the solution is stirred and dissolved, and 17.2g of sodium acetate is added; stirring the reaction solution at room temperature for 4 hours;
2) stopping the reaction, and sequentially adding 200ml of water and 100ml of ethyl acetate into the reaction solution for extracting the water phase for 3 times; after combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
3) distilling off ethyl acetate under reduced pressure at 45-50 ℃ to obtain an intermediate-1, wherein the intermediate-1 can be directly put into subsequent reaction without further treatment;
and (3) substitution reaction:
Figure FDA0002657744610000012
4) sequentially adding 100ml of DMF, 122.6 g of intermediate and 18.7g of NCS into a 500ml round-bottom flask, and heating and reacting at 40 ℃ for 2 hours after the mixture is stirred and dissolved;
5) stopping the reaction, and cooling the solution to room temperature; slowly adding 200ml of water, and separating out solids; continuously stirring and cooling to 5 ℃; filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate-2-1; the intermediate-2-1 can be directly put into subsequent reaction without further treatment;
elimination & cyclization reaction:
Figure FDA0002657744610000013
6) in a 500ml round-bottom flask, adding 150ml of DMF, 2-125.5 g of intermediate and 35.0g of trifluoromethyl ethylene intermediate in turn under the condition of stirring; after the mixture solution is dissolved, 13.2g of triethylamine is added, and the reaction is continued for 10 hours at room temperature;
7) stopping the reaction, adding 200ml of water into the reaction solution, and sequentially adding 100ml of ethyl acetate and 3 times of extraction water phase into the reaction solution; after combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) distilling the ethyl acetate under reduced pressure at 45-50 ℃ to obtain an intermediate-2 crude product; intermediate-2 after recrystallization of the crude product from ethyl acetate/petroleum ether.
2. A method for producing an isoxazoline intermediate, characterized in that: the method comprises the following steps:
hydroxylamine oximation reaction
Figure FDA0002657744610000021
1) 150ml of toluene, 50ml of water and 020.0 g of intermediate are sequentially added into a 500ml round-bottom flask, and 7.7g of hydroxylamine hydrochloride is added after the solution is stirred and dissolved; stirring the reaction solution under the condition of heating reflux for 2 hours;
2) the reaction was stopped, the phases were separated and the toluene phase was washed with 100ml × 3 times of water; drying the toluene organic phase with anhydrous sodium sulfate;
3) evaporating toluene at 75-80 ℃ under reduced pressure to obtain an intermediate-1; the intermediate-1 can be directly put into subsequent reaction without further treatment;
substitution reaction
Figure FDA0002657744610000022
4) Adding 200ml of acetonitrile, 120.6 g of intermediate and 17.6g of NBS into a 500ml round-bottom flask in sequence, and heating and refluxing for 2 hours after the mixture is stirred and dissolved;
5) stopping the reaction, and cooling the solution to room temperature; slowly adding 400ml of water, and separating out solids; continuously stirring and cooling to 5 ℃; filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate-2-1; the intermediate-2-1 can be directly put into subsequent reaction without further treatment;
elimination & cyclization reaction
Figure FDA0002657744610000031
6) In a 500ml round bottom flask, 150ml of acetonitrile, 2 to 125.3 g (0.08mol) of intermediate-and 26.4g (0.96mol) of trifluoromethyl ethylene intermediate were added in this order with stirring; after the mixture solution is dissolved, adding 9.1g (0.09mol) of triethylamine, heating and refluxing for continuous reaction for 3 hours;
7) stopping the reaction, adding 300ml of water into the reaction solution, and sequentially adding 100ml of ethyl acetate and 3 times of extraction water phase into the reaction solution; after combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) distilling the ethyl acetate under reduced pressure at 45-50 ℃ to obtain a crude intermediate 2; the crude product was recrystallized from ethyl acetate/petroleum ether and intermediate-235.7 g, HPLC purity 99.6%, yield 91.6%.
3. A method for producing an isoxazoline intermediate, characterized in that: the method comprises the following steps:
hydroxylamine oximation reaction
Figure FDA0002657744610000032
1) Sequentially adding 250ml of DMF, 100ml of water and 034.0 g of intermediate into a 500ml round-bottom flask, adding 15.3g of hydroxylamine hydrochloride after the solution is stirred and dissolved, and then adding 29.4g of potassium acetate; stirring the reaction solution at 50 ℃ to react for 2 hours;
2) stopping the reaction, and sequentially adding 300ml of water and 100ml of ethyl acetate into the reaction solution, and extracting the water phase for 3 times; after combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
3) distilling off ethyl acetate under reduced pressure at 45-50 ℃ to obtain an intermediate-1; the intermediate-1 can be directly put into subsequent reaction without further treatment;
MS(m/z):[M+H]+=186.1;
substitution reaction
Figure FDA0002657744610000041
4) Adding 250ml of acetonitrile, 134.1g of intermediate and 27.0g of NCS into a 500ml round-bottom flask in sequence, and heating and refluxing for 2 hours after the mixture is stirred and dissolved;
5) stopping the reaction, and cooling the solution to room temperature; slowly adding 500ml of water, and separating out solids; continuously stirring and cooling to 5 ℃; filtering and separating the solid, and drying the solid in vacuum at the temperature of 55-60 ℃ to obtain an intermediate-2-1; the intermediate-2-1 can be directly put into subsequent reaction without further treatment;
elimination & cyclization reaction
Figure FDA0002657744610000042
6) Adding 300ml of acetonitrile, 2-136.9 g of intermediate and 56.2g of trifluoromethyl ethylene intermediate into a 500ml round-bottom flask in turn under the condition of stirring; after the mixture solution is dissolved, 18.9g of triethylamine is added, and the mixture is heated at 60 ℃ to continue to react for 5 hours;
7) stopping the reaction, adding 600ml of water into the reaction solution, and sequentially adding 200ml of ethyl acetate and 3 times of extraction water phase into the reaction solution; after combining the ethyl acetate phases, the organic phase was dried over anhydrous sodium sulfate;
8) distilling the ethyl acetate under reduced pressure at 45-50 ℃ to obtain an intermediate-2 crude product; intermediate-2 after recrystallization of the crude product from ethyl acetate/petroleum ether.
CN201910292049.1A 2019-04-12 2019-04-12 Method for preparing isoxazoline intermediate and isoxazoline Active CN110028462B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910292049.1A CN110028462B (en) 2019-04-12 2019-04-12 Method for preparing isoxazoline intermediate and isoxazoline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910292049.1A CN110028462B (en) 2019-04-12 2019-04-12 Method for preparing isoxazoline intermediate and isoxazoline

Publications (2)

Publication Number Publication Date
CN110028462A CN110028462A (en) 2019-07-19
CN110028462B true CN110028462B (en) 2021-03-23

Family

ID=67238184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910292049.1A Active CN110028462B (en) 2019-04-12 2019-04-12 Method for preparing isoxazoline intermediate and isoxazoline

Country Status (1)

Country Link
CN (1) CN110028462B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111689919A (en) * 2020-07-22 2020-09-22 天津市中升挑战生物科技有限公司 Synthetic method of isoxazoline anthelmintic
CN111675667A (en) * 2020-07-22 2020-09-18 天津市中升挑战生物科技有限公司 Preparation method of isoxazoline anthelmintic
WO2022016490A1 (en) * 2020-07-24 2022-01-27 Elanco Us Inc. Process for lotilaner intermediate
CN112457267B (en) * 2020-11-27 2023-09-05 麦蒂辛生物医药科技成都有限公司 Preparation method of isoxazoline insecticide
CN113735681B (en) * 2021-10-11 2023-12-12 丽珠集团新北江制药股份有限公司 Florarana intermediate and method for preparing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149695A (en) * 2008-07-09 2011-08-10 日产化学工业株式会社 Process for production of isoxazoline-substituted benzoic acid amide compound
CN105906655A (en) * 2011-11-21 2016-08-31 安纳考尔医药公司 Isoxazoline derivatives used in the control of ectoparasites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149695A (en) * 2008-07-09 2011-08-10 日产化学工业株式会社 Process for production of isoxazoline-substituted benzoic acid amide compound
CN105906655A (en) * 2011-11-21 2016-08-31 安纳考尔医药公司 Isoxazoline derivatives used in the control of ectoparasites

Also Published As

Publication number Publication date
CN110028462A (en) 2019-07-19

Similar Documents

Publication Publication Date Title
CN110028462B (en) Method for preparing isoxazoline intermediate and isoxazoline
CN109879826B (en) Preparation method of isoxazoline insecticide
CA2954276C (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
CZ20004167A3 (en) Process for preparing isoxazoles
CN112457267B (en) Preparation method of isoxazoline insecticide
CN106749072A (en) The preparation method of clomazone
CN108586399B (en) Synthesis method of feloxicib
CN113735681A (en) Flurarana intermediate and method for preparing flurarana by using same
WO2003072552A1 (en) Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
CN115433140B (en) Synthetic method of Aforana
KR100672790B1 (en) Process for producing erythro-3-amino-hydroxybutyric acid derivatives
CN113372286B (en) Method for preparing 1-phenyl-5-mercapto tetrazole by one-step method
WO2005030738A1 (en) Improved process for the preparation of intermediates useful for the preparation of zonisamide
CN117510428A (en) Preparation process method of isoxazoline substituted benzamide compound
TWI749046B (en) Method for preparing substituted 2,3-dihydro-1-benzofuran derivatives
US7482476B2 (en) Process for the preparation of 5-cyanophthalide starting from 5-carboxyphthalide
CN115304472A (en) Synthetic method of intermediate 4-bromo-2-methylbenzoic acid of Freund Lei Lana
JP2001502298A (en) Methods and new intermediates
CN111825583A (en) Preparation method of isoxazole herbicide intermediate
CN116199605A (en) Synthesis method of 5-chloro-2-hydroxy-dimethylbenzenesulfonamide
CN115819303A (en) Preparation method of compound 3-fluoro-4-isothiocyanato-2-trifluoromethyl benzonitrile
CN114380781A (en) Preparation method of 2-cyano-8-nitro-4-oxo-4H-1-benzopyran
CN113372235A (en) Process for preparing 1-amino-2-phenylcyclopropanecarboxylic acid
CN117447346A (en) Synthesis method of lidocaine
CN114957147A (en) Preparation method of isoxazoline derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant